Remove Communication Remove Diabetes Remove White Paper
article thumbnail

Vertex signs licence deal with CRISPR Therapeutics for diabetes therapies

Pharmaceutical Technology

Vertex Pharmaceuticals has signed a new non-exclusive licensing agreement with CRISPR Therapeutics to expedite the development of its hypoimmune cell therapies to treat type 1 diabetes (T1D). A Phase I/II study of VCTX211 has been commenced and is currently ongoing. It originated under the partnership of CRISPR Therapeutics and ViaCyte.

article thumbnail

Lilly and ProQR to expand genetic medicine development agreement

Pharmaceutical Technology

The latest development comes after Lilly and Sosei Heptares signed a partnership for developing small molecules that modulate new G protein-coupled receptor targets linked to diabetes and metabolic diseases. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The “Medical Bypass”: new drugs to strike obesity

Pharmaceutical Technology

The drug was approved to treat type 2 diabetes mellitus in May. High rates of obesity place a major burden on healthcare systems as the condition is associated with many major health complications like type 2 diabetes, hypertension, non-alcoholic fatty liver disease, and other bodily dysfunctions. Anti-obesity therapeutic landscape.

article thumbnail

The “Medical Bypass”: new drugs to strike obesity

Pharmaceutical Technology

The drug was approved to treat type 2 diabetes mellitus in May. High rates of obesity place a major burden on healthcare systems as the condition is associated with many major health complications like type 2 diabetes, hypertension, non-alcoholic fatty liver disease, and other bodily dysfunctions. Anti-obesity therapeutic landscape.

article thumbnail

Innovative Healthcare Advertising Strategies: Transforming Pharma Marketing in the Digital Era

Pharma Marketing Network

Patient-Centric Approaches: The shift towards patient empowerment has revolutionized the way pharma brands communicate. Imagine a diabetes patient sharing their experience with Ozempicit resonates far better than generic ads. White Papers and Webinars: Provide HCPs with resources that dive into drug efficacy and research.

Dosage 52
article thumbnail

Revolutionizing Digital Marketing in Pharma: Strategies for Success

Pharma Marketing Network

From email marketing to targeted ads, make sure every piece of communication is relevant and adds value. Example: If you’re promoting a diabetes medication, use keywords like “Type 2 diabetes treatment options” and link to authoritative sources like Pharma Marketing News. They don’t want generic ads or irrelevant emails.

article thumbnail

Dawn of a new indication: how to study drugs for aging 

Pharmaceutical Technology

For example, in the Targeting Aging with Metformin (TAME) Trial , a series of six-year studies, the diabetes drug metformin will be studied for its effects in preventing age-related conditions such as cardiovascular disease, cancer, impaired cognition, and mortality. Please check your email to download the Report.

Labelling 145